Comparative outcomes of extracorporeal membrane oxygenation for COVID-19 delivered in experienced European centres during successive SARS-CoV-2 variant outbreaks (ECMO-SURGES): an international, multicentre, retrospective cohort study
An erratum to this article was published (Lancet Respir Med, Mar 2023 ↗)
Authors' conclusion
Although crude mortality did not differ between variants, adjusted risk of death was highest for patients treated with ECMO infected with the delta variant of SARS-CoV-2.
Study context
- Population
- Adults with laboratory-confirmed SARS-CoV-2 infection receiving extracorporeal membrane oxygenation (ECMO) for acute respiratory distress syndrome (ARDS) in 21 experienced ECMO centres in eight European countries, Jan 1, 2020–Sept 30, 2021
- Participants
- 1,345 adults · 21 centres
- Exposure
- ECMO outcomes by SARS-CoV-2 variant
- Wild typen = 686reference
- Alphan = 391
- Deltan = 195
- Othern = 73
- Outcome
- Mortality after ECMO initiation
- Follow-up
- 90 days
Methodological detailsinternational, multicentre
- International
- Multicentre
Main finding
As reported in the abstract
90-day mortality
- Overall 90-day mortality
- 42% (569 of 1345)
Observational data: associations, not effects.
Further findings
Mortality by pandemic period
- Second semester of 2020
- 50%
- Other semesters
- 40%
Independent predictors of mortality
- Age, immunocompromised status, longer ICU admission-to-intubation time, need for RRT, higher SOFA haemodynamic score, PaCO2 and lactate before ECMO
Original publication
Comparative outcomes of extracorporeal membrane oxygenation for COVID-19 delivered in experienced European centres during successive SARS-CoV-2 variant outbreaks (ECMO-SURGES): an international, multicentre, retrospective cohort study. Lancet Respir Med. Published 11 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →